CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 86 enrolled
Drug / intervention
Lebrikizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05369403
NCT05369403Phase 3Completed
CompareCT.gov

An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Eli Lilly and Company·interventional·Posted May 11, 2022·Updated Feb 25, 2026

In Brief

A Phase 3 clinical trial evaluating Lebrikizumab for Atopic Dermatitis. Completed, enrolled 86 participants across 37 sites.

Detailed Summary

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedMay 11, 2022
Enrollment StartDec 19, 2022
Primary CompletionJan 11, 2024
Study CompletionFeb 5, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.1 years ago

Interventions

Lebrikizumabdrug

Administered SC